This site uses cookies. You can read how we use them in our privacy policy.

pulmonary fibrosis

and infection

sign up to receive our news and updates

  • This form collects your name and email address so that we can keep you updated with news and information about Breathing Matters. Please check our Privacy Policy to see how we protect and manage your data.

Stories from June, 2021


  • Related articles
  • Categories
  • Archives

Article in The Guardian Respiratory Health Supplement

Professor Jo Porter, our Medical Director, has had an article published in the Respiratory Health Supplement in The Guardian today (22.6.21), explaining research into the impact of COVID-19 on lung fibrosis

This is what Prof Porter had to say:

A study is underway to assess the impact of COVID-19 on lung fibrosis development.  Interstitial lung disease (ILD), or lung fibrosis, diagnosed by CT scan, causes difficulty breathing by affecting the delicate membrane separating the blood and air in the lungs.  Joanna Porter, Professor of Respiratory Medicine at University College London, says there are more than 200 causes of ILD, including asbestos, mould, feathers, underlying conditions such as rheumatoid arthritis, and infection.  COVID-19 infection may be the latest contributor to ILD development.

COVID-19 impact – Dividing her research role with clinical work as head of the national NHS centre for ILD at University College London Hospitals, Professor Porter says there are an estimated 16,000 new ILD cases per year but this could be an underestimate as some people may not know they have the disease.  Specialists agree that current evidence is limited, however there is concern regarding the impact of COVID-19 on ILD and lung fibrosis patients. What is known is that patients with the most severe form of ILD – idiopathic pulmonary fibrosis (IPF) – do less well if they catch the virus.  The UK ILD Post-COVID Study is now following up hospitalised and non-hospitalised post-COVID patients to see how many develop a new ILD as a result of SARS-CoV-2 infection.  This UKRI funded multicentre study will look at patients in the PHOSP study who had a CT scan three months after their initial infection and compare that with their 12-month follow-up scan to identify ongoing and resolved issues.  Although we do not know the final figures, unpublished preliminary data from UCLH suggest around 4% of patients may be affected.

Professor Porter is also Medical Director of Breathing Matters, a UCLH charity, dedicated to finding a cure for all forms of ILD/pulmonary fibrosis. She points out that anything we learn from post-COVID ILD will almost certainly help other patients with lung fibrosis. Breathing Matters has continued vital research throughout the pandemic to address these critical questions.

Read the full Respiratory Health Campaign to find out more about key respiratory conditions, new innovations and the importance of good air quality

You can also read more on the online campaign at


How COVID-19 Is Helping Research Into Pulmonary Fibrosis?

The interstitial lung diseases (ILDs) are a group of over 200 different diseases that may result in lung inflammation or (in the worst case) pulmonary fibrosis (PF). There are many different aetiologies for ILD/PF and in some cases, we do not know the cause, so called ‘idiopathic’.

One of the questions that we at Breathing Matters want to answer is – can COVID-19 give you pulmonary fibrosis? There are a few clues that this might be the case. Other coronaviruses such as Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) have been reported to cause PF in a small percentage of patients, but of course the numbers of patients affected by SARS-CoV-2, the virus that causes COVID-19, will be much greater so, even if only a small percentage are affected, the numbers may still be very large. The diagnosis of ILD/PF is suggested by a clinical finding of breathlessness and abnormal lung function. The diagnosis is then confirmed with a CT scan of the chest.

Initial studies from China, Italy and the UK have remarkably similar findings. Of patients with COVID-19 discharged from a hospital in China, nearly half had abnormal lung function (Mo X, et al. European Respiratory Journal 55: 2001217, 2020).  Data from Leeds of patients with COVID-19 discharged from hospital showed that the majority (75% of those admitted to intensive care, and 65% of those admitted to the regular wards) still suffered from fatigue at 6 to 8 weeks post discharge. The number suffering from continual breathlessness was also high (70% of those admitted to intensive care, and 45% of those admitted to the ward).  (Halpin S et al. Journal Medical Virology, First published: 30 July 2020, DOI: (10.1002/jmv.26368).  An Italian study from Rome found that at 60 days around 55% of patients were suffering from fatigue and 40% from breathlessness.  It is unclear what is the cause of these high levels of breathlessness, but a study from Austria is following their patients up in more detail at 6, 12 and 24 weeks after discharge. So far, they have found that at 6 weeks 47% of patients are short of breath and this falls to 39% at 12 weeks. In addition, 33% have abnormal lung function suggestive of lung fibrosis, but this falls to 22% at 12 weeks. Of course, to diagnose lung fibrosis requires at CT scan of the chest and they found that CT scans suggested an interstitial lung disease (ILD) or lung fibrosis in 88% falling to 56% at 12 weeks. However, it is also important to know how much of the lung is affected, and many of the studies do not clarify this, but just comment on whether ILD is present or not. The result is that it is hard to know whether these patients had minimal or significant ILD changes on the CT scan. Clearly, Breathing Matters will be looking out for the 24 week data.

Our own experience is that of around 800 patients seen at UCLH with COVID-19, in the first wave approximately 4-6% have persistent or slowly resolving CT changes at 12 months suggestive of interstitial lung involvement. The incidence of ILD may be less in subsequent waves because of the wider use of the steroid, dexamethasone, in patients with COVID-19 pneumonitis. Currently, our main priority is to analyse the scans of 20,000 patients who were hospitalised with COVID-19 and are taking part in the national PHOSP study, to see how common the development of ILD/ PF is in a much larger group of patients.  We will also look at 10,000 patients who had COVID-19 but were not hospitalised. This study funded by UKRI is a multicentre study that will look at the incidence of post COVID-ILD, investigate how much of the lung is affected and what the critical contributory factors are. It may be that this virus and the enormous numbers of patients that have been infected will shed some light on the pathogenesis of other ILD/PF diseases.​

We will keep you informed of any new findings.